Colorectal cancer (CRC) is the second most common cancer in Western countries. Hereditary forms only correspond to 5% of CRC burden. Recently, genome-wide association studies have identified common low-penetrant CRC genetic susceptibility loci. Early-onset CRC (CRC<50 years old) is especially suggestive of hereditary predisposition although 85-90% of heritability still remains unidentified. CRC<50 patients (n 5 191) were compared with a late-onset CRC group (CRC>65 years old) (n 5 1264). CRC susceptibility variants at 8q23.3 (rs16892766), 8q24.21 (rs6983267), 10p14 (rs10795668), 11q23.1 (rs3802842), 15q13.3 (rs4779584), 18q21 (rs4939827), 14q22.2 (rs4444235), 16q22.1 (rs9929218), 19q13.1 (rs10411210) and 20p12. 3 (rs961253) were genotyped in all DNA samples. A genotype-phenotype correlation with clinical and pathological characteristics in both groups was performed. Risk allele carriers for rs3802842 [Odds ratio (OR) 5 1.5, 95% confidence interval (CI) 1.1-2.05, P 5 0.0096, dominant model) and rs4779584 (OR 5 1.39, 95% CI 1.02-1.9, P 5 0.0396, dominant model) were more frequent in the CRC<50 group, whereas homozygotes for rs10795668 risk allele were also more frequent in the early-onset CRC (P 5 0.02, codominant model). Regarding early-onset cases, 14q22 (rs4444235), 11q23 (rs3802842) and 20p12 (rs961253) variants were more associated with family history of CRC or tumors of the Lynch syndrome spectrum excluding CRC. In our entire cohort, sum of risk alleles was significantly higher in patients with a CRC family history (OR 5 1.40, 95% CI 1.06-1.85, P 5 0.01). In conclusion, variants at 10p14 (rs10795668), 11q23.1 (rs3802842) and 15q13.3 (rs4779584) may
Introduction
Colorectal cancer (CRC) is the second leading cause of cancer-related death in Western countries (1) . As other complex diseases, CRC is caused by both genetic and environmental factors. Although environmental factors, such as smoking and diet are undoubtedly major risk factors for CRC, twin studies have shown that 30% of the variation in CRC susceptibility involves inherited genetic differences (2, 3) . Familial adenomatous polyposis and Lynch syndrome (LS) are the more frequent hereditary CRC syndromes and they are caused by germline mutations in APC or MUTYH and DNA repair genes (MLH1, MSH2, MSH6 and PMS2), respectively. Hereditary CRC forms account only for a minority of the total CRC burden (5%). The genetic components involved in these less frequent hereditary forms were successfully identified in the past two decades and they correspond to rare highly penetrant alleles that predispose to CRC (4) .
According to the common disease-common variant hypothesis, a majority of the heritability in CRC may be explained by multiple common genetic variants with a low-moderate effect on cancer susceptibility (5). The common disease-common variant hypothesis has been recently vindicated by genome-wide association studies and, so far, 14 common low-penetrant genetic loci have been identified for CRC susceptibility on 8q24. 21 (6) (7) (8) . In addition, some of these variants appear to be associated with some clinical and familial features, which could have potential implications for screening and surveillance strategies (9, 10) .
Early-onset CRC (,50 years old) is especially suggestive of a hereditary predisposition and it can be used in genetic association studies to increase likelihood of finding susceptibility variants. We have shown previously that LS-and MUTYH-associated CRC account for only 15-20% of the early-onset CRC cases (11) . Therefore, a considerable proportion of heritability still remains unidentified in this high-risk group. Hypothesizing that some of these susceptibility variants could be distinctively related to early-onset CRC, the aims of our study were firstly to assess the prevalence of 10 common, lowpenetrance CRC susceptibility variants at 8q23.3 (rs16892766), 8q24.21 (rs6983267), 10p14 (rs10795668), 11q23.1 (rs3802842), 15q13.3 (rs4779584), 18q21 (rs4939827), 14q22.2 (rs4444235), 16q22.1 (rs9929218), 19q13.1 (rs10411210) and 20p12.3 (rs961253) in a group of unselected early-onset CRC patients with no involvement of hereditary syndromes, and secondly, to perform a genotypephenotype correlation of these variants with clinical and pathological characteristics.
Materials and methods

Study population
We retrospectively recruited all patients ,50 years old diagnosed with CRC (early-onset CRC) who were surgically treated at two Spanish centers between 1995 and 2007 (Hospital Clínic of Barcelona and Hospital of Donostia), with available archival formalin-fixed paraffin-embedded samples (11) . Patients with personal history of colorectal polyposis, inflammatory bowel disease, biallelic MUTYH mutations, LS diagnosis (germline mutation carriers) or LS-suspected (mismatch repair deficiency without MLH1 promoter methylation) were excluded. A total of 115 patients from both centers were considered for this study. Additionally, 76 early-onset CRC patients were also included from the EPICOLON cohort (12) using the same previous exclusion criteria.
Abbreviations: CI, confidence interval; CRC, colorectal cancer; LS, Lynch syndrome; MSI, microsatellite instability; OR, odds ratio; SNP, single-nucleotide polymorphism. Clinical and pathological data were obtained from each patient's medical record, including gender, age at diagnosis, previous CRC or LS-spectrum tumor, synchronous CRC or adenoma and tumor features, such as microsatellite instability high histology (MSI-high histology or MSI-histology), location, tumor-node-metastasis stage and degree of differentiation. MSI-high histology was defined as presence of tumor-infiltrating lymphocytes, Crohn-like lymphocytic reaction, mucinous/signet-ring differentiation or medullary growth pattern. Family history of cancer, including at least first-degree and seconddegree relatives, was acquired either from the medical record or by phone contact. Positive family history was considered if one or more first-degree or second-degree relative(s) had cancer. A group of 1264 late-onset CRC (.65 years old) patients also from the EPICOLON cohort with the same previous exclusion criteria was used to detect the distinctive presence of susceptibility variants and familial, clinical and pathological features between both groups.
The study was approved by the institutional ethics committee of each participating hospital. Written informed consent was obtained at CRC diagnosis on a systematic basis. Next-of-kin consent was obtained in deceased cases if informed consent was missing.
DNA isolation
Genomic DNA samples from each patient were obtained from formalin-fixed, paraffin-embedded normal colonic mucosa or peripheral blood when available. DNA was isolated using the QIAamp Tissue Kit or QIAamp DNA Blood Kit (Qiagen, Courtaboeuf, France) according to the manufacturers' instructions.
Single-nucleotide polymorphism genotyping
Ten single-nucleotide polymorphisms (SNPs) from chromosomal regions 8q23.3 (rs16892766), 8q24.21 (rs6983267), 10p14 (rs10795668), 11q23.1 (rs3802842), 15q13.3 (rs4779584), 18q21.1 (rs4939827), 14q22.2 (rs4444235), 16q22.1 (rs9929218), 19q13.1 (rs10411210) and 20p12.3 (rs961253), which have been previously reported to be associated with CRC genetic susceptibility by genome-wide association studies, were genotyped in all DNA samples; rs stands for reference SNP. All SNPs genotyped are listed in Table I , including genomic location and major/minor/risk alleles. Sum of risk alleles corresponded to the number of risk alleles present in an individual in the 10 susceptibility variants (hypothetical range 0-20). Genotyping was performed using TaqMan allelic discrimination (Applied Biosystems) or single-base primer extension chemistry matrix-assisted laser desorption/ionization time-of-flight mass spectrometry detection (Sequenom, San Diego, CA) according to the manufacturer's instructions.
Statistical analysis
Departure from Hardy-Weinberg equilibrium of the genotype frequencies for all SNPs was tested using a fast exact test as described by Wigginton et al. (13) . Allelic and genotypic frequencies were calculated for each SNP. Population stratification is the presence of a systematic difference in allele frequencies between subpopulations in a population, possibly due to different ancestry, especially in the context of association studies. Population stratification can be a problem for association studies, such as case-control studies, where the association found could be due to the underlying structure of the population and not a disease-associated locus. There was no sign of underlying population stratification in EPICOLON as tested by an independent study (14) .
A polygenic model was built summing the number of risk alleles from each SNP for each patient. The risk allele for each SNP was defined based on literature. The distribution of risk alleles was represented by a histogram and a t-test was used to compare early-and late-onset groups.
The association of each SNP with early-and late-onset was estimated using logistic regression models. Odds ratios (OR) and corresponding 95% confidence intervals (95% CI) were calculated for the codominant, dominant and log-additive inheritance model (per allele OR) with the SNPassoc R package (15) . A descriptive analysis for all clinicopathological factors was executed for early-and late-onset groups separately. Inter-group comparisons were performed using the Fisher exact test. Associations between SNP genotypes and sum of risk alleles with clinical and pathological variables were also estimated using logistic regression models. For all statistical analyses, results were considered significant at the 0.05 threshold. Multiple testing correction was calculated for 10 SNPs (P 5 0.005). Results are presented without correction for multiple testing to prevent type II error.
Results
Clinical and pathological characteristics in early-and late-onset CRC One hundred and ninety-one early-onset CRC patients (CRC,50) were included in this study and they were compared with a late-onset CRC group (CRC.65) comprising 1264 patients. Table II shows the main features of patients in both groups.
Regarding differences between onset groups, previous neoplasm and synchronous CRC were more frequently present in the CRC.65 patients (P 5 0.003 and P 5 0.049, respectively). Also, proximal CRC location was more prominent in the CRC.65 group (P 5 0.002). On the other hand, advanced tumor-node-metastasis stage was more frequent in the CRC,50 group (P , 0.001).
CRC genetic susceptibility variants in early-and late-onset CRC: number of risk alleles SNP genotyping was successful in all patients and all SNPs were in Hardy-Weinberg equilibrium (P . 0.05). Allele frequencies considering risk allele homozygotes (RR), heterozygotes (Rr) and non-risk homozygotes (rr) for the 10 variants are described in Table I . We first tested if the sum of risk alleles in the 10 SNPs was different between early-and late-onset CRC because the cumulative effect of risk alleles is expected to be more pronounced than for individual SNPs. Distribution of risk alleles in both groups is represented in Figure 1 . Earlyonset CRC patients carried on average 10 risk alleles (10.01 ± 1.79; range [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , which was similar to the number carried by patients in the CRC.65 group (9.8 ± 1.93; range 3-16; P50.143). Median number of risk alleles was 10 in both early-onset and late-onset CRC groups, although carriers of 10 risk alleles were more frequent in the early-onset group.
CRC genetic susceptibility variants in early-and late-onset CRC: individual SNPs When considering the 10 risk alleles individually, we observed differences in some specific allele frequencies depending on the CRC age of onset. Allelic distribution, ORs and corresponding 95% CI for each SNPs in both groups are shown in Table III (codominant and logadditive inheritance models) and Table IV (dominant inheritance  model) . Indeed, risk alleles located at 11q23 (rs3802842) and 15q13 (rs4779584) were significantly enriched in the early-onset CRC group. Risk allele carriers for rs3802842 were more frequent in the CRC,50 group (OR 5 1.5, 95% CI 1.1-2.05, P 5 0.0096, dominant model) as well as rs4779584 risk allele carriers (OR 5 1.39, 95% CI 1.02-1.9, P 5 0.0396, dominant model). In addition, homozygotes for rs10795668 risk allele were also more frequent in the early-onset CRC (codominant model, P 5 0.02). The rest of SNPs showed a similar distribution in early-and late-onset CRC patients.
CRC genetic susceptibility variants in early-and late-onset CRC: correlation with clinical and pathological features Besides exploring the differences regarding the distribution of the 10 genetic susceptibility variants for CRC between early-and late-onset groups, we also investigated the differential distribution of the risk alleles for these variants depending on the presence of selected clinical and pathological characteristics in these two onset age groups. Eight of the analyzed SNPs showed statistically significant differences in CRC,50 or CRC.65 regarding at least one clinical or pathological patient's features (Supplementary Table is available at Carcinogenesis Online), whereas variants at 8q23.3 (rs16892766) and 15q13.3 (rs4779584) showed no distinct association between onset groups. Interestingly, risk alleles for the 8q24.21 (rs6983267) variant were predominantly present in the CRC.65 group in patients with a positive CRC family history (FH CRC). On the other hand, risk alleles for the 10p14 (rs10795668) variant were mainly present in the CRC.65 group in patients without a positive family history of LS-spectrum tumors not including CRC (FH LS no CRC) and patients with a synchronous adenoma (Sync Adenoma). Regarding the 11q23.1 (rs3802842), risk alleles were differentially present in both age groups in patients regarding FH CRC, whereas risk alleles for this variant were more frequent in the CRC.65 group in patients with a positive MSI-high histology (MSI-histology). Surprisingly, risk alleles for the 18q21.1 (rs4939827) variant were more common in female patients of the CRC,50 group. Risk alleles of the 14q22.2 (rs4444235) variant were more present in the CRC,50 group in patients without FH LS no CRC. When analyzing tumor-node-metastasis staging, risk alleles for the 16q22.1 (rs9929218) variant were more common in patients of the CRC,50 group with less advanced tumors (I þ II stages). Regarding CRC location, risk alleles for the 19q13.1 (rs10411210) variant were more present in patients of the CRC.65 group with proximal tumors. Finally, risk alleles for the 20p12.3 (rs961253) variant were predominantly present in the CRC,50 group in patients with FH LS no CRC and without MSI-histology.
Additionally, besides performing a genotype-phenotype correlation for individual SNPs, we also did the same analysis for the sum of risk alleles. Since number of risk alleles showed no statistically significant differences when comparing CRC,50 and CRC.65 in our cohort, we performed this correlation for both groups jointly. Interestingly, those patients having Sync Adenoma, a first-degree relative with CRC, FH CRC,50 or FH CRC showed a higher mean of risk alleles in the crude analysis. When results were adjusted for age, only first-degree relative with CRC (OR 5 1.58, 95% CI 1.18-2.11, P 5 0.0021) and FH CRC (OR 5 1.40, 95% CI 1.06-1.85, P 5 0.0177) remained statistically significant. Distribution of sum of risk CRC genetic susceptibility variants in early-onset patients alleles for FH CRC and sporadic CRC groups is shown in Figure 2 , showing a clear enrichment of CRC risk alleles in the first group. No other clinical and pathological variables were associated with carrying a higher number of risk alleles in our entire cohort.
Discussion
Our study compared the prevalence of 10 common, low-penetrance CRC susceptibility variants in a group of unselected early-onset (CRC,50) and late-onset (CRC.65) patients without involvement of hereditary CRC syndromes. Also, we performed a genotypephenotype correlation of these variants with clinical and pathological characteristics in both groups. Regarding age categories, it has been suggested that early-onset CRC (CRC,50) represents a biologically distinct disease, with clinicopathological and molecular differences compared with patients with older onset of disease. Around 75-80% of early-onset CRC cases have a proficient mismatch repair system and a yet unidentified genetic predisposition (11) . Also, the start age in CRC screening programs is 50 years old. A CRC,40 cut-off only included 36 patients in our series (70-75% of early-onset cases corresponded to 40-49 years old patients) and it was considered not suitable. Therefore, CRC,50 seemed a priori the more appropriate age group for early-onset CRC. Also, the CRC.65 cut-off seemed adequate since most CRC occur in patients older than 65 years and the mean onset age in the EPICOLON cohort was 70 years.
Although the number of risk alleles was slightly higher in earlyonset compared with late-onset CRC, we did not observe statistically significant differences in the mean number of risk alleles between these groups. In contrast, a previous report showed a significant increase in the number of risk alleles in familial cases with early-onset disease (16) . However, enrichment for risk alleles in solitary early-onset CRC was not observed in the same study. On the other hand, Niittymäki et al. (17) did not found an association of higher risk allele number with early-onset either in familial or sporadic early-onset cases. Remarkably, we observed that the number of risk alleles was higher in those patients with first-degree family history of CRC regardless their onset age, which provides evidence to support that these risk variants are involved in inherited CRC susceptibility but probably not exclusively in the CRC,50 group. In this regard, both Middeldorp et al. (16) and Niittymäki et al. (17) reported also a clear association of increasing number of risk variants and familial CRC. We detected a different distribution of CRC susceptibility variants at 10p14 (rs10795668), 11q23.1 (rs3802842) and 15q13.3 (rs4779584) in the CRC,50 group when compared with the CRC.65 group. Therefore, it could be hypothesized that these variants may have a predominant role in predisposition to early-onset. Recently, two independent studies reported specific association of CRC susceptibility variants to an onset age group in agreement with our results. von Holst et al. (18) detected that risk alleles at 8q24.21 (rs6983267), 10p14 (rs10795668) and 19q13.1 (rs10411210) were associated to older age (.60 years old), younger age ( 60 years old) in sporadic cases and younger age, respectively. On the other hand, He et al. (19) detected a significant effect modification by age, with the effects of variants at 11q23.1 (rs3802842), 14q22.2 (rs4444235) and 15q13.3 (rs4779584), being stronger on CRC/ adenoma risk developed before 66 years old, whereas the effect of variants at 8q24.21 (rs6983267) and 20p12.3 (rs961253) was stronger at older ages. Therefore, our results for rs3802842, rs4779584 and rs10795668 are to some extent in agreement with these previous results. In addition, rs3802842 has been reported to act as a modifier increasing the risk of developing CRC in LS, an inherited condition characterized by early-onset CRC (20, 21) . However, it is worth mentioning that these observed associations would not be present if Bonferroni correction for multiple testing was applied (P 5 0.005). Our study design compared two groups of cases and controls were not included. However, the genetic variants tested in our study, besides being extensively demonstrated to be associated with CRC risk by previous studies (6) (7) (8) , they have also been tested for association with CRC risk in the Spanish population (Fernández-Rozadilla et al., submitted for publication), and most of them have been replicated, including 11q23 (rs3802842), 15q13 (rs4779584) and 10p14 (rs10795668).
Regarding the potential functional implications of the differentially distributed variants, rs10795668 is located in a gene desert at the 10q14 region and there are no predicted genes within 0.4 Mb. The predicted gene, FLJ3802842, is the closest to this variant but there is still no evidence of a functional link between them. On the other hand, rs3802842 maps to a region in 11q23.1, encompassing four genes: (6) . Regarding correlation of the 10 genetic susceptibility variants with clinical and pathological CRC characteristics in the CRC,50 and CRC.65 groups, eight of the analyzed SNPs showed statistically significant differences. Some variants showed correlation with familial aggregation for CRC (rs6983267, rs3802842 and rs961253). These associations were only present in the CRC,50 group (rs4444235), the CRC.65 group (rs6983267 and rs10795668) or in both groups (rs3802842 and rs961253). Previous studies have shown that the rs6983267 risk variant is more common in patients with a family history of CRC (9, 22, 23) as it was demonstrated previously for the rs4939827 risk variant at 18q21.1 (24) .
Moreover, risk variants for rs3802842 and rs961253 were differentially distributed in patients with MSI-histology in their tumor. MSIhistology characteristics include mucin production. In a previous article by Ghazi et al. (10) , mucin production correlated with presence of the rs961253 risk allele and it was hypothesized that this variant may be associated with mucin-producing tumors. We also find sitespecific differences in risk associated to rs10411210, more present in patients of the CRC.65 group with proximal tumors. In this regard, several studies (19, (25) (26) (27) have reported notable site-specific differences in risk associated to rs10795668, rs3802842 and rs4444235. Our results also suggest an association of the risk variant at 10p14 (rs10795668) with the presence of synchronous adenomas in the CRC.65 group. Some susceptibility variants have been previously related to the presence of synchronous adenomas [rs10808555, rs6983267 and rs7837328 on 8q24 and rs9929218 on 16q22.2 (9, 28) ]. In addition, risk alleles for rs9929218 were more common in patients of the CRC,50 group with less advanced tumors (I þ II stages). Other SNPs (rs16892766 and rs3802842) have been previously linked to advanced CRC (9, 29) . Finally, an association of rs4939827 with gender was present in the CRC,50 group, as it was previously seen in a previous report (30) . In a very recent article, 16 genetic loci associated so far with CRC were examined in relation to a preferential association with tumor site, stage, degree of differentiation and MSI. Statistically significant associations were found, including rs3802842 with microsatellite stable rectal disease, rs9929218 and rs4779584 with microsatellite stable colonic disease and rs4444235 with MSI colonic disease (31) .
Concerning strengths and limitations, our study could be considered as the first to thoroughly evaluate CRC susceptibility variants in early-onset patients in order to identify if any of them could be more predominantly linked to CRC risk in this age subgroup. On the other hand, it should be also pointed out that our results should be considered cautiously due to the relative small number of early-onset CRC patients included. Also, since our results should be formally considered not statistically significant when applying multiple testing correction, additional studies in other CRC cohorts are needed to confirm the potential association of susceptibility variants with early-onset CRC.
Summarizing, we have found evidence that susceptibility variants on 11q23 (rs3802842), 15q13 (rs4779584) and 10p14 (rs10795668) may be related to early-onset CRC. Additionally, risk alleles on 14q22 (rs4444235), 11q23 (rs3802842) and 20p12 (rs961253) seem to be differentially associated with early-onset cases depending on having a family history of CRC or tumors of the LS spectrum excluding CRC; they could be relevant due to potential implications for screening and surveillance strategies in this high-risk group. Finally, several susceptibility alleles appear to be related with some patient's personal and familiar features. It is therefore essential to further establish correlations between CRC susceptibility variants discovered in genome-wide association studies and patients' personal and familial characteristics. 
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